- Home
- IVP vs SLRX Comparison
IVP vs SLRX Comparison
Compare IVP & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- SLRX
- Stock Information
- Founded
- IVP 2020
- SLRX N/A
- Country
- IVP United States
- SLRX United States
- Employees
- IVP N/A
- SLRX N/A
- Industry
- IVP Diversified Commercial Services
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- SLRX Health Care
- Exchange
- IVP Nasdaq
- SLRX Nasdaq
- Market Cap
- IVP 3.4M
- SLRX 3.6M
- IPO Year
- IVP 2023
- SLRX N/A
- Fundamental
- Price
- IVP $0.99
- SLRX $4.29
- Analyst Decision
- IVP
- SLRX
- Analyst Count
- IVP 0
- SLRX 0
- Target Price
- IVP N/A
- SLRX N/A
- AVG Volume (30 Days)
- IVP 166.9K
- SLRX 441.7K
- Earning Date
- IVP 11-12-2025
- SLRX 11-13-2025
- Dividend Yield
- IVP N/A
- SLRX N/A
- EPS Growth
- IVP N/A
- SLRX N/A
- EPS
- IVP N/A
- SLRX N/A
- Revenue
- IVP $15,292,904.00
- SLRX N/A
- Revenue This Year
- IVP N/A
- SLRX N/A
- Revenue Next Year
- IVP N/A
- SLRX N/A
- P/E Ratio
- IVP N/A
- SLRX N/A
- Revenue Growth
- IVP N/A
- SLRX N/A
- 52 Week Low
- IVP $0.63
- SLRX $3.64
- 52 Week High
- IVP $24.61
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- IVP 51.76
- SLRX 51.50
- Support Level
- IVP $0.93
- SLRX $3.86
- Resistance Level
- IVP $1.00
- SLRX $4.58
- Average True Range (ATR)
- IVP 0.07
- SLRX 0.37
- MACD
- IVP -0.01
- SLRX -0.14
- Stochastic Oscillator
- IVP 28.60
- SLRX 52.47
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.